Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa

Thorax

Volumn 72, Issue 7, 2017, Pages 666-667

  Waters, Elaine M ^a   Neill, Daniel R ^a   Kaman, Basak ^a   Sahota, Jaspreet S ^b   Clokie, Martha R J ^b   Winstanley, Craig ^a   Kadioglu, Aras ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Bacterial Infection; Cystic Fibrosis; Respiratory Infection

Indexed keywords

ANIMAL; BACTERIAL COUNT; BAGG ALBINO MOUSE; BIOFILM; CHRONIC DISEASE; DISEASE MODEL; MOUSE; PHAGE THERAPY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; TIME FACTOR;

ANIMALS; BIOFILMS; CHRONIC DISEASE; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; MICE; MICE, INBRED BALB C; PHAGE THERAPY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; TIME FACTORS;

EID: 85028015134     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2016-209265     Document Type: Article

References (10)

1. Pirnay JP, De Vos D, Verbeken G, et al. The phage therapy paradigm: pret-a-porter or sur-mesure Pharm Res 2011;28:934-7
2. Wright A, Hawkins CH, Anggard EE, et al. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 2009;34:349-57
3. Rose T, Verbeken G, Vos DD, et al. Experimental phage therapy of burn wound infection: difficult first steps. Int J Burns Trauma 2014;4:66-73.
4. Danis-Wlodarczyk K, Vandenheuvel D, Jang HB, et al. A proposed integrated approach for the preclinical evaluation of phage therapy in Pseudomonas infections. Sci Rep 2016;6:28115
5. Debarbieux L, Leduc D, Maura D, et al. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis 2010;201:1096-104
6. Morello E, Saussereau E, Maura D, et al. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS ONE 2011;6:e16963
7. Henry M, Lavigne R, Debarbieux L. Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections. Antimicrob Agents Chemother 2013;57:5961-8
8. Alemayehu D, Casey PG, McAuliffe O, et al. Bacteriophages phiMR299-2 and phiNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio 2012;3:e00029-12.
9. Fothergill JL, Neill DR, Loman N, et al. Pseudomonas aeruginosa adaptation in the nasopharyngeal reservoir leads to migration and persistence in the lungs. Nat Commun 2014;5:4780
10. Sahota JS, Smith CM, Radhakrishnan P, et al. bacteriophage delivery by nebulization and efficacy against phenotypically diverse pseudomonas aeruginosa from cystic fibrosis patients. J Aerosol Med Pulm Drug Deliv 2015;28:353-60.